title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Methods | PMC10512773 | |||
Study participants | AKI, sepsis | SEPSIS | This was a single-center double-blind randomized clinical trial that screened all consecutive patients admitted for AKI who met the diagnostic criteria for sepsis and had been evaluated by the Nephrology Department at the Hospital Civil de Guadalajara Fray Antonio Alcalde, a large referral center that cares for patient... | PMC10512773 |
Definitions | nausea, diarrhea, vomiting, rash, AKI | ADVERSE EVENT, KIDNEY DISEASE | AKI was defined as an increase in serum creatinine (sCr) levels according to Kidney Disease Improving Global Outcomes (KDIGO) [All comorbidities and clinical data were prospectively collected during the first evaluation.Adverse events were prespecified according to those most frequently reported with the use of probiot... | PMC10512773 |
Study outcomes | ADVERSE EVENTS | The primary outcome was KFR on day 7 (sCr return to <0.30 mg/dL from the baseline value). Secondary outcomes included variables related to KFR during the treatment and the follow-up period, namely, the change in urinary volume, percentage of decrease in sCr levels, in-hospital mortality, mortality during follow-up, KRT... | PMC10512773 | |
Randomization and treatment assignments | AKI | Randomization was carried out by a computer-generated stratified sequence with a 1:1 allocation ratio in blocks of 5, with the groups stratified by sex. The researchers, who used a concealed opaque envelope system, performed group assignment after informed consent was obtained. A double-blind, double-dummy design was u... | PMC10512773 | |
Interventions | Patients in the intervention group received 2 capsules of Simbin-RNL® or 2 capsules of placebo (maltodextrin) every 24 h for 7 consecutive days. The gastro-resistant Simbin-RNL® capsule contained 540 mg of a mixture of | PMC10512773 | ||
Statistical analysis | death, SD | REGRESSION | Categorical variables are presented as numbers and percentages, and comparisons between groups were performed with the chi-square or Fisher exact test as appropriate. The Shapiro–Wilk test was performed to assess data distribution; continuous variables are summarized as the means ± standard deviations (SD) if the data ... | PMC10512773 |
Results | AKI, sepsis | SEPSIS | From February 2019 to March 2022, 621 patients with AKI underwent nephrology consultation, and 123 did not have sepsis or they lacked variables of interest for the analysis; thus, 498 were assessed for eligibility, among whom 372 did not meet inclusion criteria, and 34 did not sign the consent form; therefore, 92 patie... | PMC10512773 |
Primary outcome | The KFR by day 7 is presented in Primary objective, kidney function recovery during the 7 days of the study trial.Primary and Secondary objectives. | PMC10512773 | ||
Secondary outcomes | uremia | REGRESSION, SECONDARY, VOLUME OVERLOAD, UREMIA | The results of the secondary outcomes are shown in Secondary outcomes, A) Survival, B) serum urea, and C) urinary output, during the 7 days of the study trial.A total of 17 (19%) patients required KRT during the study follow-up period, which was mostly due to uremia, volume overload, and electrolyte abnormalities; this... | PMC10512773 |
Additional outcomes of interest | Potassium levels decreased, and chloride levels increased during the study in both groups, but they did not differ significantly between intervention groups. Only sodium levels decreased in the probiotic group (134 ± 5.9), and they increased in the placebo group (137 ± 5.8) ( | PMC10512773 | ||
Adverse events | ADVERSE EVENTS, ADVERSE EVENT | The prespecified adverse events during the study period are presented in Adverse events during the 7 days of study period. | PMC10512773 | |
Discussion | CKD, fibrosis, intestinal dysbiosis, kidney dysfunction, sepsis-induced AKI, AKI, sepsis | ADVERSE EVENTS, FIBROSIS, KIDNEY DYSFUNCTION, SECONDARY, SEPSIS | In this double-blind randomized clinical trial carried out in patients with AKI secondary to sepsis, we found for the first time that the administration of probiotics for 7 days did not improve KFR compared with placebo treatment, but it had a trend to decrease the mortality rate, in addition to having an acceptable sa... | PMC10512773 |
Limitations and strengths | inflammation, AKI septic | INFLAMMATION | Our results must be interpreted with caution, as this was a single-center study without an The strengths of the study lie in its design and the adequate adherence of the patient groups to treatment; to our knowledge, this is the first randomized control trial of AKI septic patients treated with probiotics [In the next ... | PMC10512773 |
Conclusion | AKI, sepsis | SEPSIS | In AKI associated with sepsis, the administration of probiotics for 7 days was safe, and compared with placebo, it did not improve renal function, but there was a trend toward decreased mortality. | PMC10512773 |
Ethics approval and consent to participate | DEL | The study was approved by the Institutional Review Board HCG/CEI-1342/18, was registered with the Clinical Trials identifier NCT03877081, 03/15/2019 Informed consent was obtained from all subjects. All methods were carried out in accordance with relevant guidelines and regulations. All experimental protocols were appro... | PMC10512773 | |
Authors’ contributions | RCD | CPH, MAY, GCA | JSCI, MIE, AMG-G, ACH, RCD, GCA, were responsible for the design, analysis and interpretation of the data. EMHB, ACRM, FRA, MLPM, MPC, JATG, CPH, GNB, RMG, LAV, KRL and GGG were responsible for data collection. All authors have read and approved the manuscript.The preprint version of the manuscript was posted in May 30... | PMC10512773 |
Disclosure statement | No potential conflict of interest was reported by the author(s). | PMC10512773 | ||
Availability of data and materials | Are available in the historical archive of the Hospital Civil Fray Antonio Alcalde. If any information is requested, please contact Principal Investigator Dr. Jonathan Chávez-Iñiguez ( | PMC10512773 | ||
References | PMC10512773 | |||
Background | PONV, postoperative nausea and vomiting | The use of multimodal pharmacological prophylactic regimes has decreased postoperative nausea and vomiting (PONV) in general but it still occurs in over 60% of female patients after bariatric surgery. This study aimed to evaluate the efficacy of ST36 acupoint injection with anisodamine in prevention of PONV among femal... | PMC10338617 | |
Methods | PONV, depression, anxiety | COMPLICATIONS | Ninety patients undergoing laparoscopic sleeve gastrectomy were randomly allocated to anisodamine or control group at the ratio of 2:1. Anisodamine or normal saline was injected into Zusanli (ST36) bilaterally after induction of general anesthesia. The incidence and severity of PONV were assessed during the first 3 pos... | PMC10338617 |
Results | vomiting | Baseline and perioperative characteristics were comparable between two groups. In the anisodamine group, 25 patients (42.4%) experienced vomiting within postoperative 24 h compared with 21 (72.4%) in the control group (relative risk 0.59; 95% confidence interval 0.40–0.85). Time to first rescue antiemetic was 6.5 h in ... | PMC10338617 | |
Conclusions | obesity, nausea | OBESITY | The addition of ST36 acupoint injection with anisodamine significantly reduced postoperative vomiting without affecting nausea in female patients with obesity undergoing laparoscopic sleeve gastrectomy. | PMC10338617 |
Supplementary Information | The online version contains supplementary material available at 10.1007/s00464-023-10037-6. | PMC10338617 | ||
Keywords | PONV, postoperative nausea and vomiting, arthritis, shock | CARDIAC ARRHYTHMIAS, CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, ARTHRITIS, SHOCK | More than 30% of postoperative patients in general still suffer from postoperative nausea and vomiting (PONV) within 24 h after surgery, and can be as high as 60–80% of high-risk patients based on Apfel score [Previous in vivo and in vitro studies have found that anisodamine can have therapeutic benefits in cardiac arr... | PMC10338617 |
Materials and methods | PMC10338617 | |||
Trial design and ethics | This single-center prospective, randomised, double-blinded study was approved by the Ethics Committee of the Second Affiliated Hospital of Anhui Medical University, Anhui province, China (Chairperson Prof. Yanghua Tian) on December 2, 2021 (Ref YX2021-114) in accordance to the principles of the Declaration of Helsinki.... | PMC10338617 | ||
Participants | OSAHS, obesity, psychological disorder, endocrine disorder, obstructive sleep apnea hypopnea syndrome, rash, liver, coagulation derangements, allergic diathesis | OBESITY, OBSTRUCTIVE SLEEP APNEA HYPOPNEA SYNDROME, GASTROESOPHAGEAL REFLUX, ENDOCRINE DISORDER, DISEASES OF THE HEART, SYSTEMIC INFECTION | All adult female patients with an American Society of Anesthesia (ASA) physical status I–III, scheduled for elective LSG surgery were screened. The exclusion criteria: contraindications to acupoint injection, such as a local rash at the site of skin injection or systemic infection, any history of allergic diathesis for... | PMC10338617 |
Randomization and blinding | All participants were randomly assigned to anisodamine group (bilateral ST36 acupoint injection with anisodamine) or control group (bilateral ST36 injection with normal saline) in a 2:1 ratio. The randomization was computer-generated by using The allocation sequence was concealed until the end of data collection, and t... | PMC10338617 | ||
Standardized anesthesia management | Dexmedetomidine (0.5 μg kg | PMC10338617 | ||
ST36 acupoint injection and PONV management | PONV, Acupuncture | Acupuncture treatment was performed by a licensed acupuncturist who had at least 5 years of acupuncture experience. All participants received bilateral ST36 acupuncture injection with anisodamine (5 mg/1 ml per site) or normal saline (1 ml per site) [All patients received prophylaxis for PONV with dexamethasone (10 mg ... | PMC10338617 | |
Outcomes | PONV, depression, vomiting, anxiety | SECONDARY, POSTOPERATIVE COMPLICATIONS | The primary outcome is the incidence of vomiting within the first 24 h postoperatively.The secondary outcomes include: the time to the first rescue antiemetic; the incidence of PONV assessed at 2, 6, 48, and 72 h after surgery; the severity of PONV measured by the Verbal Rating Scale (VRS) (none, mild, moderate, or sev... | PMC10338617 |
Statistical analysis | postoperative vomiting, vomiting | Based on the incidence of postoperative vomiting in our pilot study, the proportions of patients who experienced vomiting within 24 h after surgery in the control group and anisodamine group were 80% and 40% respectively (Table S1). The sample size was calculated to be 84 patients (28 in control and 56 in anisodamine),... | PMC10338617 | |
Discussion | PONV, vomiting, patients-specific | In this trial, anisodamine was creatively used on ST36 acupoint injection in female patients during LSG. During the first postoperative 24 h, we successfully observed a significant reduction of the incidence of vomiting, an increase of the time to first rescue antiemetic, as well as less rescue antiemetic in patients w... | PMC10338617 | |
Strengths and limitations | postoperative vomiting, postoperative nausea., PONV, Vomiting | This trial, based on previous studies, simplifies the procedure and duration of acupuncture and provides a comparable preventive effect on postoperative vomiting, which contributes to the popularization of acupuncture in preventing PONV. The results also provide strong evidence using anisodamine for PONV prevention.Thi... | PMC10338617 | |
Conclusions | PONV | ST36 acupoint injection with anisodamine had incremental benefit when used as part of combination prophylaxis for reducing PONV. It could be a new option contained in multimodal prophylactic antiemetic regime in female patients undergoing laparoscopic sleeve gastrectomy. | PMC10338617 | |
Funding | This study was supported by Basic and clinical cooperative research promotion plan of Anhui Medical University (Grant 2019xkjT026), the National Natural Science Foundation of China (Grant 81801050), Scientific Research Platform Base Construction and Promotion Project of Anhui Medical University (Grant 2020xkjT060), Key... | PMC10338617 | ||
Declarations | PMC10338617 | |||
Disclosures | Dr. Qi Xue, Qijing Xing, Ling Dong, Min Guo, Xiaoyan Zhang, Xinchun Wei, Dr. Benli Jia, Prof. Yong Wang, Hong Chen, Prof. Xianwen Hu, Prof. Hong Liu, Prof. Ye Zhang, Prof. Gordon Tin Chun Wong, Dr. Chunxia Huang have no conflicts of interest or financial ties to disclose. | PMC10338617 | ||
References | PMC10338617 | |||
Keywords | Open access funding provided by SCELC, Statewide California Electronic Library Consortium | PMC10412661 | ||
Introduction | TNBC, mTNBC, breast cancers, tumor | TRIPLE-NEGATIVE BREAST CANCER, TUMOR, BREAST CANCER, CHEMOTHERAPY EFFECTS, SOLID TUMORS | Triple-negative breast cancer (TNBC) accounts for 10–15% of all breast cancers and is characterized by lack of estrogen receptor (ER), progression receptor (PR), and human epidermal growth factor receptor 2 (HER2) overexpression. TNBC is molecularly heterogeneous, and metastatic TNBC (mTNBC) carries poor prognosis due ... | PMC10412661 |
Methods | PMC10412661 | |||
Study design and patient population | TNBC, mTNBC | ONCOLOGY, DISEASE, IMMUNODEFICIENCY | This open-label single institutional phase I trial for patients with metastatic TNBC was conducted between March 2016 and November 2019 with institutional review board (IRB) approval in accordance with the World Medical Association Declaration of Helsinki, International Conference on Harmonization Good Clinical Practic... | PMC10412661 |
Study procedure | Eligible patients received pembrolizumab 200 mg IV with doxorubicin 50–60 mg/m | PMC10412661 | ||
Clinical response statistics | toxicities | SECONDARY | The primary objective of the study was to evaluate ORR of pembrolizumab plus doxorubicin. The secondary objective was to assess clinical benefit rate (CBR) (no progression for > 24 weeks), progression-free survival (PFS), and overall survival (OS). Additional secondary endpoints were to assess the safety and tolerabili... | PMC10412661 |
Tumor immune biomarkers | tumor, Tumor, Breast Cancer | TUMOR, TUMOR, BREAST CANCER | Tumor biopsies were formalin-fixed paraffin-embedded (FFPE). Percentage of stromal TILs (sTILs) in tumor was evaluated using hematoxylin and eosin (H&E) diagnostic sections per International Immuno-Oncology Biomarker Working Group on Breast Cancer Guidelines [ | PMC10412661 |
Peripheral blood immune correlatives | SEPARATION | Peripheral blood was collected at baseline (pre-treatment), C2D1, and post-cycle 3 (C4D1 or C6D1) for flow cytometry analysis. Peripheral blood was obtained using heparin collection tubes, and peripheral blood mononuclear cells (PBMCs) were isolated within 6 h using Ficoll-Paque Separation according to manufacturer’s i... | PMC10412661 | |
Correlative studies statistics | Graphs and statistics were performed using GraphPad Prism 8.4.3. Statistics were generated using unpaired two-tailed Student T tests or multiple comparisons T tests with Dunnet’s or Holm-Sidak corrections as described. Calculated p values are displayed as * | PMC10412661 | ||
Results | PMC10412661 | |||
Patients | anthracycline-naive, death, respiratory failure, chronic respiratory disease | RESPIRATORY FAILURE, CHRONIC RESPIRATORY DISEASE | Between March 2016 and November 2019, a total of 10 patients were enrolled and treated with doxorubicin and pembrolizumab. The trial was stopped early due to poor accrual because of difficulty in identifying patients who were anthracycline-naive. All 10 patients were included in the safety evaluation. One patient with ... | PMC10412661 |
Treatment | The first 3 patients received doxorubicin at 50 mg/m | PMC10412661 | ||
Response and survival | sepsis, death, neutropenia, Tumor | SEPSIS, NEUTROPENIA, TUMOR | Of 10 patients treated, one patient (age 87) developed neutropenia, sepsis, and death after 1Relative Change in Tumor Size ( | PMC10412661 |
Exceptional responder | ER/PR-positive, adenopathy, high-grade TNBC | DISEASE, MAY, ADENOPATHY, RESIDUAL DISEASE, PATHOLOGY, HER2-NEGATIVE BREAST CANCER | Patient was initially diagnosed with ER/PR-positive, HER2-negative breast cancer in 2002. She was treated with surgery, adjuvant cyclophosphamide methotrexate fluorouracil (CMF), and radiation therapy, followed by 5 years of adjuvant tamoxifen. In 2011, patient who recurred with high-grade TNBC received neoadjuvant doc... | PMC10412661 |
Treatment associated toxicities | neutropenia | ADVERSE EVENTS, ADVERSE EVENT, NEUTROPENIA | Grade 3–4 adverse events (AEs) per CTCAE 4.0 were neutropenia Grade 2–4 adverse event with attributions in “definite”, “possible”, “probable” per CTCAE 4.0 | PMC10412661 |
Tumor immune biomarkers | PD, tumor | DISEASE, TUMOR | PD-L1 (22C3) testing showed 4 patients who were PD-L1 positive, 4 patients who were PD-L1 negative, and 2 patients who did not have PD-L1 results. Stromal TILs analysis of available tumor tissue was performed for 4 patients and showed 1 CR patient with 90% TILs (lymph node), 1 UPR patient with 5% TILs (axillary mass), ... | PMC10412661 |
PMBC immune cell composition | PD, CR/PR/SD | Baseline and on-treatment characteristics of peripheral blood immune cell composition were analyzed in response to therapy. Two high parameter (> 28) spectral cytometry panels were designed to identify both broad immune subsets and detailed T cell subsets. At baseline, we found no association of response and frequencie... | PMC10412661 | |
T cell compositional changes over the course of treatment | heterogenous, PD, tumor, CM | TUMOR | Given the increased frequency of T cells from pre-treatment to C2D1, we next set to dissect features of T cell subsets in greater detail over the course of therapy and in context of tumor response. Within CD8 + and CD4 + T cell populations, we found no significant differences in frequencies of canonical naïve, central ... | PMC10412661 |
Expansion of a proliferative, exhausted CD8 + T cell population over the course of treatment | PD | Among all patients, the increase in CD8 + proliferating T cells was greatest in the patient with CR (1.7-fold change vs. mean 0.8 in PD/SD/PR), which led us to further investigate this T cell subset. From pre-treatment to C2D1, CD8 + proliferating T cells increased from 5.2 to 9.2% in the patient with CR but reduced fr... | PMC10412661 | |
Discussion | PD, mTNBC, pembrolizumab-treated melanoma | PROLIFERATIVE, BREAST CANCER | Although limited by small sample size, the results of the current trial provide evidence that doxorubicin can be safely combined with pembrolizumab with Several studies have demonstrated utility of chemo-immunotherapy combination in treatment of mTNBC. FDA accelerated approval was granted to atezolizumab in March 2019 ... | PMC10412661 |
Supplementary Information | PD, SD, CM | DISEASE PROGRESSION, DISEASE | Below is the link to the electronic supplementary material.Supplemental Fig. 1. Broad immune characterization of peripheral blood of patients treated with doxorubicin and pembrolizumab at baseline. A) Pre-treatment peripheral blood samples were examined by flow cytometry for lymphocyte composition frequencies, includin... | PMC10412661 |
Acknowledgements | Cancer | CANCER | Merck provided research funding this study. The COH Biostatistics Core and Analytical Cytometry Core was supported by the National Cancer Institute of the National Institutes of Health (P30CA033572). This work was also supported by the National Institutes of Health (NIH)/National Cancer Institute (NCI) grant RO1CA20691... | PMC10412661 |
Author contributions | GS designed and supervised the study; JW and YY supervised data collection and analysis, manuscript preparation; XG, JL and SEY provided clinical data, study operations support, and manuscript preparation; PHF, CR, and YC provided statistical design and data analysis; CE, WG, and PPL performed and interpreted correlati... | PMC10412661 | ||
Funding | Cancer | CANCER | Open access funding provided by SCELC, Statewide California Electronic Library Consortium. This study was funded by Merck and supported by City of Hope Comprehensive Cancer Center. | PMC10412661 |
Data availability | All data and materials are presented in the article and additional files. Raw data are available upon request. | PMC10412661 | ||
Declarations | PMC10412661 | |||
Conflict of interest | Dr. Yuan has contracted research sponsored by Imugene, Minerva, Merck, Novartis, Genentech, and Pfizer, is a consultant for Pfizer, Immunomedics, and is on the Speakers Bureau for Genentech, AstraZeneca, Daiichi Sankyo, and Gilead. The other authors declare that they have no competing interests. | PMC10412661 | ||
Ethics approval and consent to participate | The study was approved by City of Hope IRB registered under NCT02648477. Procedures were performed in accordance with the ethical standards of the City of Hope, the national research committee, and the 1964 Declaration of Helsinki and International Conference on Harmonization Guidelines for Good Clinical Practice and l... | PMC10412661 | ||
Consent for publication | Not applicable. | PMC10412661 | ||
References | PMC10412661 | |||
Abstract | MPD, ESRD | END-STAGE RENAL DISEASE, ESRD, COMPLICATIONS | These authors contributed equally to this work.During urgent-start peritoneal dialysis (USPD) in end-stage renal disease (ESRD) patients, both adequate dialysis and skill training for fluid exchange are essential. However, automated peritoneal dialysis (APD) alone or manual fluid exchange peritoneal dialysis (MPD) alon... | PMC10269400 |
Keywords | PMC10269400 | |||
Introduction | bacteremia, PD, MPD, ESRD | END-STAGE RENAL DISEASE, ESRD | Peritoneal dialysis (PD) is an effective treatment for patients with end-stage renal disease (ESRD). PD initiation is usually recommended at least two weeks after peritoneal dialysis catheter (PDC) implantation [Urgent-start peritoneal dialysis (USPD) is defined as the initiation of PD within two weeks of PDC implantat... | PMC10269400 |
Materials and methods | PMC10269400 | |||
Design | WEST | This single-center, prospective, randomized, open-label, controlled study was approved by the Ethics Committee of West China Hospital of Sichuan University (approval number: 2020-891) and registered in the Chinese Clinical Trials Registry ( | PMC10269400 | |
Participants | ESRD, PD, electrolyte disorders, sepsis, acute heart failure | SEPSIS, RECRUITMENT, ELECTROLYTE DISORDER, COMPLICATIONS, UREMIC ENCEPHALOPATHY, WEST, SYSTEMIC INFECTION, HEART, ESRD, DISEASES, ACUTE HEART FAILURE | Nephrologists provided patients with ESRD requiring urgent dialysis with detailed information on possible treatment modalities. Individuals who preferred PD and were suitable for PD were eligible if they were aged 18–75 years. The study recruitment period was from March to December 2021 at the Department of Nephrology,... | PMC10269400 |
PDC implantation and PD schemes | PD | All patients received Tenckhoff catheters and prophylactic antibiotics were administered preoperatively. Two experienced nephrologists performed catheter implantations using open dissection, and those through laparoscopy were performed by a surgeon. All the PDC were implanted at the day surgery center. USPD was initiat... | PMC10269400 | |
Termination of the study | PD, hernia, peritonitis | PERITONITIS, COMPLICATIONS, LEAKAGE | When patients experienced complications, such as leakage and mechanical complications of PDC, which disturbed normal PD therapy, medication and conservative treatment were administered, and PD was suspended for 3 days. In addition, the patients continued the study and completed the five-day USPD after such complication... | PMC10269400 |
Outcome measurements | catheter-related infection, exit-site infection, inguinal hernia, PD, tunnel infection, peritonitis, Catheter-related infections | PERITONITIS, COMPLICATIONS, LEAKAGE | The primary outcomes included clearance of small-molecule uremic toxins and PD technical survival rate. All patients underwent laboratory measurements before and after USPD, including serum levels of creatinine, blood urea nitrogen, albumin, sodium, potassium, magnesium, phosphorus, carbon dioxide combining power (COSe... | PMC10269400 |
Statistical analysis | All statistical analyses were performed using the Statistical Package for Social Sciences (SPSS) software (version 26.0). Continuous variables, which conformed to the normal distribution, were expressed as mean ± standard deviation, and comparisons between groups were performed using the Student’s | PMC10269400 | ||
Results | PMC10269400 | |||
Demographic and baseline characteristics | MPD | Overall, 74 patients were enrolled in this study. Among these, 60 completed the study, including 29 and 31 patients in the MPD and A-MPD groups, respectively (Flow diagram of enrollment, randomization, and follow-up of patients. MPD: manual fluid exchange peritoneal dialysis; A-MPD: combination of automated peritoneal ... | PMC10269400 | |
Comparison of the laboratory parameters | After the five-day USPD treatment, the serum levels of creatinine, blood urea nitrogen, albumin, potassium, magnesium, and iPTH decreased dramatically (Self-comparison of laboratory parameters before and after USPD within groups.COComparison of the difference of laboratory parameters before and after USPD between the t... | PMC10269400 | ||
Short-term PD-related complications | COMPLICATIONS | In total, 21 patients experienced short-term complications during USPD treatment (PD-related complications during 5-day USPD treatment.PDC: peritoneal dialysis catheter.Reasons of quitting the study.PDC: peritoneal dialysis catheter. | PMC10269400 | |
Time expenditure of nurses treating PD and patients’ test scores | PD | The mean time expenditure for dialysate exchange by nurses for the A-MPD group was 248.45 ± 6.20 min during the five days (including two manual fluid exchanges and connection and disconnection of cycler per day). The mean time expenditure in the MPD group was 256.86 ± 11.70 min/day (including four manual fluid exchange... | PMC10269400 | |
PD technique survival and patient survival | PD, peritonitis | PERITONITIS | Here, 60 patients were followed up for 6 months. Two patients in the A-MPD group developed peritonitis during follow-up; one underwent removal of the PDC and was switched to hemodialysis, while the other resumed peritoneal dialysis after antibiotic treatment. In contrast, one patient in the MPD group received renal tra... | PMC10269400 |
Discussion | PD, ’ mistakes, MPD | COMPLICATION, COMPLICATIONS, LEAKAGE | This study is the first to combine APD with MPD in the treatment of USPD. Compared with MPD, the A-MPD mode had a better effect on removing small-molecule toxins. Simultaneously, the A-MPD mode could effectively save time for nurses treating PD and improve the skill training of patients. The incidence of short-term com... | PMC10269400 |
Conclusion | PD, acidosis, hyperkalemia | ACIDOSIS | The combination of APD with MPD during USPD treatment had more advantages in removing small-molecule toxins, correcting hyperkalemia and acidosis, reducing the burden of nurses by saving time and improving patients’ skills in fluid exchange. Therefore, this mode could be recommended as an adoptable and suitable PD moda... | PMC10269400 |
Acknowledgments | The authors express their sincere appreciation to all colleagues involved in the study for their participation in this trial. The authors would also like to acknowledge all the patients who participated in this trial. | PMC10269400 | ||
Authors’ contributions | XXX | XXX and HXQ enrolled patients in the study, evaluated the effect and safety, and collected the data. HXQ, PL, LX, and ZXL performed manual fluid exchange, APD, patient education, and training. XXX, WXF, and ZZY contributed to data analysis and manuscript preparation. LZ contributed to the concept, design, data analysis... | PMC10269400 | |
Ethics approval and consent to participate | WEST | The study was approved by the Medical Ethics Committee of the West China Hospital of Sichuan University, Sichuan, China. This study followed the Declaration of Helsinki and written informed consent was obtained from the participants. | PMC10269400 | |
Disclosure statement | No potential conflict of interest was reported by the author(s). | PMC10269400 | ||
Data availability statement | The datasets used and analyzed during the current study are available from the corresponding author upon reasonable request. | PMC10269400 | ||
References | PMC10269400 | |||
Evaluation and scale of operating procedures | The total score is 200 points. The patient is considered to be qualified if he or she got more than 120 points. | PMC10269400 | ||
Introduction | The COVID-19 pandemic exposed people to significant and prolonged stress. The psychosocial impacts of the pandemic have been well recognised and reported in high-income countries (HICs) but it is important to understand the unique challenges posed by COVID-19 in low- and middle-income countries (LMICs) where limited in... | PMC10105919 | ||
Methods and analysis | post-traumatic, post-traumatic stress | This cross-sectional study uses an online survey to administer a novel COVID Psychosocial Impacts Scale (CPIS) alongside established measures of psychological distress, post-traumatic stress, well-being and post-traumatic growth in the appropriate language. Participants will include adults aged 18 years and above, recr... | PMC10105919 | |
Ethics and dissemination | Ethical approval was granted by the Human Ethics Committee, University of Otago, New Zealand (Ref. No. 21/102). In addition, international collaborators obtained local authorisation or ethical approval in their respective host universities before data collection commenced.Participants will give informed consent before ... | PMC10105919 | ||
Strengths and limitations of this study | post-traumatic | RECRUITMENT | This cross-sectional observational study will make a significant contribution to understanding the psychosocial impacts of the COVID-19 pandemic in seven low- and middle-income countries with different pandemic impacts.This study will quantify psychometric measures in countries where there is currently limited access t... | PMC10105919 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.